{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:50:31Z","timestamp":1790182231860,"version":"4.1.0"},"reference-count":238,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021729","name":"Medizinische Fakult\u00e4t der Albert-Ludwigs-Universit\u00e4t Freiburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hyperactivation of the RAS-RAF-MEK-ERK cascade -\u00a0a mitogen-activated protein kinase pathway \u2013 has a well-known association with oncogenesis of leading tumor entities, including non-small cell lung cancer, colorectal carcinoma, pancreatic ductal adenocarcinoma, and malignant melanoma. Increasing evidence shows that genetic alterations leading to RAS-RAF-MEK-ERK pathway hyperactivation mediate contact- and soluble-dependent crosstalk between tumor, tumor microenvironment (TME) and the immune system resulting in immune escape mechanisms and establishment of a tumor-sustaining environment. Consequently, pharmacological interruption of this pathway not only leads to tumor-cell intrinsic disruptive effects but also modification of the TME and anti-tumor immunomodulation. At the same time, the importance of ERK signaling in immune cell physiology and potentiation of anti-tumor immune responses through ERK signaling inhibition within immune cell subsets has received growing appreciation. Specifically, a strong case was made for targeted MEK inhibition due to promising associated immune cell intrinsic modulatory effects. However, the successful transition of therapeutic agents interrupting RAS-RAF-MEK-ERK hyperactivation is still being hampered by significant limitations regarding durable efficacy, therapy resistance and toxicity. We here collate and summarize the multifaceted role of RAS-RAF-MEK-ERK signaling in physiology and oncoimmunology and outline the rationale and concepts for exploitation of immunomodulatory properties of RAS-RAF-MEK-ERK inhibition while accentuating the role of MEK inhibition in combinatorial and intermittent anticancer therapy. Furthermore, we point out the extensive scientific efforts dedicated to overcoming the challenges encountered during the clinical transition of various therapeutic agents in the search for the most effective and safe patient- and tumor-tailored treatment approach.<\/jats:p>","DOI":"10.3389\/fonc.2022.931774","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T05:39:31Z","timestamp":1658900371000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation"],"prefix":"10.3389","volume":"12","author":[{"given":"Thomas Yul","family":"Avery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Brummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich Alexander","family":"Ruess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","volume-title":"WHO. global health estimates 2020: Deaths by cause, age, sex, by country and by region, 2000-2019","year":"2020"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.013","article-title":"Targeting the MAPK pathway in KRAS-driven tumors","volume":"37","author":"Drosten","year":"2020","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2015.10.001","article-title":"Targeting RAS-mutant cancers: is ERK the key","volume":"1","author":"Ryan","year":"2015","journal-title":"Trends Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J Cell Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002319","article-title":"p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition","volume":"9","author":"Baumann","year":"2021","journal-title":"J ImmunoTherapy Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-01008-4","article-title":"Tumor and systemic immunomodulatory effects of MEK inhibition","volume":"23","author":"Dennison","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1389-z","article-title":"Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties","volume":"62","author":"Ott","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016980","article-title":"Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK\/ERK MAPK and neutralizing interleukin-6 in progenitor cells","volume":"108","author":"Wang","year":"2006","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0448-9","article-title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","volume":"25","author":"Ascierto","year":"2019","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz113","article-title":"Phase ib study of atezolizumab combined with cobimetinib in patients with solid tumors","volume":"30","author":"Hellmann","year":"2019","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0474-7","article-title":"Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients","volume":"25","author":"Sullivan","year":"2019","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e152670","DOI":"10.1172\/JCI152670","article-title":"Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers","volume":"131","author":"Yarchoan","year":"2021","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2021.09.011","article-title":"Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial","volume":"158","author":"Zimmer","year":"2021","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.160.6.2579","article-title":"Inhibition of T cell activation by pharmacologic disruption of the MEK1\/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production","volume":"160","author":"Dumont","year":"1998","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00728-9","article-title":"Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer","volume":"8","author":"Dushyanthen","year":"2017","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.2013.52.1377","article-title":"Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges","volume":"32","author":"Hu-Lieskovan","year":"2014","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.02.019","article-title":"Phase I\/II trial of immunotherapy with durvalumab and tremelimumab with continuous or intermittent MEK inhibitor selumetinib in NSCLC: early trial report","volume":"21","author":"Gaudreau","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204382","article-title":"Signal transduction by MAP kinases in T lymphocytes","volume":"20","author":"Rincon","year":"2001","journal-title":"Oncogene"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2006.11.001","article-title":"Atypical mitogen-activated protein kinases: structure, regulation and functions","volume":"1773","author":"Coulombe","year":"2007","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol Mol Biol Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-0255-7","article-title":"ERK signalling: a master regulator of cell behaviour, life and fate","volume":"21","author":"Lavoie","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.112","article-title":"Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer","volume":"22","author":"Van Cutsem","year":"2004","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"102309","DOI":"10.1016\/j.ctrv.2021.102309","article-title":"KRAS inhibitors\u2013yes but what next? direct targeting of KRAS\u2013vaccines, adoptive T cell therapy and beyond","volume":"101","author":"Nagasaka","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.12740","article-title":"A compendium of ERK targets","volume":"591","author":"\u00dcnal","year":"2017","journal-title":"FEBS Lett"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nri1335","article-title":"Feedback regulation of lymphocyte signalling","volume":"4","author":"Reth","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1042\/BST20160135","article-title":"Deciphering the RAS\/ERK pathway in vivo","volume":"45","author":"Dorard","year":"2017","journal-title":"Biochem Soc Trans"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.8.1940","article-title":"MEK kinase activity is not necessary for raf-1 function","volume":"20","author":"H\u00fcser","year":"2001","journal-title":"EMBO J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.8.1952","article-title":"Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene","volume":"20","author":"Mikula","year":"2001","journal-title":"EMBO J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ng0797-293","article-title":"Endothelial apoptosis in braf-deficient mice","volume":"16","author":"Wojnowski","year":"1997","journal-title":"Nat Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.04.002","article-title":"C-raf, but not b-raf, is essential for development of K-ras oncogene-driven non-small cell lung carcinoma","volume":"19","author":"Blasco","year":"2011","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1417549111","article-title":"Loss of p53 induces cell proliferation via ras-independent activation of the Raf\/Mek\/Erk signaling pathway","volume":"111","author":"Drosten","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0511113103","article-title":"Diverse toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells","volume":"103","author":"Banerjee","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2007.03.009","article-title":"Mek1\/2 MAPK kinases are essential for mammalian development, homeostasis, and raf-induced hyperplasia","volume":"12","author":"Scholl","year":"2007","journal-title":"Dev Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.07.011","article-title":"Functional redundancy of ERK1 and ERK2 MAP kinases during development","volume":"12","author":"Fr\u00e9min","year":"2015","journal-title":"Cell Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nri2035","article-title":"MAPK phosphatases\u2013regulating the immune response","volume":"7","author":"Liu","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.163.12.6598","article-title":"Commitment to the CD4 lineage mediated by extracellular signal-related kinase mitogen-activated protein kinase and lck signaling","volume":"163","author":"Sharp","year":"1999","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.11.7617","article-title":"The Erk2 MAPK regulates CD8 T cell proliferation and survival","volume":"181","author":"D'Souza","year":"2008","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M502333200","article-title":"Ras-ERK MAPK cascade regulates GATA3 stability and Th2 differentiation through ubiquitin-proteasome pathway","volume":"280","author":"Yamashita","year":"2005","journal-title":"J Biol Chem"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.3.936-946.2000","article-title":"Activation of p38 mitogen-activated protein kinase in vivo selectively induces apoptosis of CD8+ but not CD4+ T cells","volume":"20","author":"Merritt","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048991","article-title":"Geranylgeranyl pyrophosphate amplifies treg differentiation via increased IL-2 expression to ameliorate DSS-induced colitis","volume":"51","author":"Pandit","year":"2021","journal-title":"Eur J Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/ni1334","article-title":"ABIN-2 is required for optimal activation of erk MAP kinase in innate immune responses","volume":"7","author":"Papoutsopoulou","year":"2006","journal-title":"Nat Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0329","article-title":"Inhibition of CD4+ CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production","volume":"108","author":"Zeiser","year":"2006","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00707","article-title":"Activation of the MEK-ERK pathway is necessary but not sufficient for breaking central b cell tolerance","volume":"9","author":"Greaves","year":"2018","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4161\/cc.7.23.7103","article-title":"Regulation of lymphocyte fate by Ras\/ERK signals","volume":"7","author":"Yasuda","year":"2008","journal-title":"Cell Cycle"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nri2133","article-title":"B-cell anergy: from transgenic models to naturally occurring anergic b cells","volume":"7","author":"Cambier","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev.immunol.021908.132541","article-title":"B cell signaling and fate decision","volume":"28","author":"Kurosaki","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031547","article-title":"Requirement for ras guanine nucleotide releasing protein 3 in coupling phospholipase c-\u03b32 to ras in b cell receptor signaling","volume":"198","author":"Oh-Hora","year":"2003","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/gad.1161904","article-title":"The generation of antibody diversity through somatic hypermutation and class switch recombination","volume":"18","author":"Li","year":"2004","journal-title":"Genes Dev"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0437996100","article-title":"Transcriptional analysis of the b cell germinal center reaction","volume":"100","author":"Klein","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.05.017","article-title":"ERK1\/2 has an essential role in b cell receptor-and CD40-induced signaling in an in vitro model of germinal center b cell selection","volume":"67","author":"Adem","year":"2015","journal-title":"Mol Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406837101","article-title":"Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity","volume":"101","author":"Harada","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051283","article-title":"BAFF regulates b cell survival by downregulating the BH3-only family member bim via the ERK pathway","volume":"202","author":"Craxton","year":"2005","journal-title":"J Exp Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2001592","article-title":"ERKs induce expression of the transcriptional repressor blimp-1 and subsequent plasma cell differentiation","volume":"4","author":"Yasuda","year":"2011","journal-title":"Sci Signaling"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1182\/blood.V126.23.3588.3588","article-title":"Kras is critical for b cell lymphopoiesis","volume":"126","author":"Zheng","year":"2015","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abc1648","article-title":"ERK phosphorylation is RAF independent in na\u00efve and activated b cells but RAF dependent in plasma cell differentiation","volume":"14","author":"Scheffler","year":"2021","journal-title":"Sci Signaling"},{"key":"B66","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bcmd.2014.01.001","article-title":"BRAF\u2013a new player in hematological neoplasms","volume":"53","author":"Machnicki","year":"2014","journal-title":"Blood Cells Mol Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1084\/jem.20200851","article-title":"B cells and cancer: To b or not to b","volume":"126","author":"Fridman","year":"2021","journal-title":"J Exp Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural killer cells and other innate lymphoid cells in cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474361","article-title":"Murine natural killer immunoreceptors use distinct proximal signaling complexes to direct cell function","volume":"121","author":"May","year":"2013","journal-title":"Blood J Am Soc Hematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401224","article-title":"PTEN is a negative regulator of NK cell cytolytic function","volume":"194","author":"Briercheck","year":"2015","journal-title":"J Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2004.12.016","article-title":"Differential roles of constitutively activated ERK1\/2 and NF-\u03baB in cytotoxicity and proliferation by human NK cell lines","volume":"5","author":"Liang","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.610789","article-title":"Transcription factors associated with IL-15 cytokine signaling during NK cell development","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-159285","article-title":"Stem cell factor and interleukin-2\/15 combine to enhance MAPK-mediated proliferation of human natural killer cells","volume":"113","author":"Benson","year":"2009","journal-title":"Blood J Am Soc Hematol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/ni0603-517","article-title":"Understanding the function of CD1-restricted T cells","volume":"4","author":"Vincent","year":"2003","journal-title":"Nat Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.01.012","article-title":"Making memory at birth: understanding the differentiation of natural killer T cells","volume":"24","author":"Engel","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e19890","DOI":"10.1371\/journal.pone.0019890","article-title":"The Ras\/MAPK pathway is required for generation of iNKT cells","volume":"6","author":"Hu","year":"2011","journal-title":"PloS One"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-014-9933-y","article-title":"The differential roles of mTOR, ERK, and JNK pathways in invariant natural killer T-cell function and survival","volume":"37","author":"Tian","year":"2014","journal-title":"Inflammation"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.1.348","article-title":"Toll-like receptor 2 is required for innate, but not acquired, host defense to borrelia burgdorferi","volume":"168","author":"Wooten","year":"2002","journal-title":"J Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.657","article-title":"Identification of a TLR-independent pathway for borrelia burgdorferi-induced expression of matrix metalloproteinases and inflammatory mediators through binding to integrin \u03b13\u03b21","volume":"177","author":"Behera","year":"2006","journal-title":"J Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e0140064","DOI":"10.1371\/journal.pone.0140064","article-title":"ERK signaling is essential for macrophage development","volume":"10","author":"Richardson","year":"2015","journal-title":"PloS One"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis332","article-title":"Macrophage p38 mitogen-activated protein kinase activity regulates invariant natural killer T-cell responses during borrelia burgdorferi infection","volume":"206","author":"Hawley","year":"2012","journal-title":"J Infect Dis"},{"key":"B83","doi-asserted-by":"publisher","first-page":"a034892","DOI":"10.1101\/cshperspect.a034892","article-title":"MAP-kinase-driven hematopoietic neoplasms: a decade of progress in the molecular age","volume":"11","author":"Chakraborty","year":"2021","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nri1996","article-title":"Steady-state and inflammatory dendritic-cell development","volume":"7","author":"Shortman","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1822","article-title":"Dendritic cell subsets in primary and secondary T cell responses at body surfaces","volume":"10","author":"Heath","year":"2009","journal-title":"Nat Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101696","article-title":"Splenic stroma-educated regulatory dendritic cells induce apoptosis of activated CD4 T cells via fas ligand-enhanced IFN-\u03b3 and nitric oxide","volume":"188","author":"Xu","year":"2012","journal-title":"J Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2175","article-title":"Extracellular signal\u2013regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells","volume":"98","author":"Puig-Kroger","year":"2001","journal-title":"Blood J Am Soc Hematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161881","article-title":"RAF\/MEK\/extracellular signal\u2013related kinase pathway suppresses dendritic cell migration and traps dendritic cells in langerhans cell histiocytosis lesions","volume":"215","author":"Hogstad","year":"2018","journal-title":"J Exp Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199802123380706","article-title":"Chemokines\u2013chemotactic cytokines that mediate inflammation","volume":"338","author":"Luster","year":"1998","journal-title":"New Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/nri1785","article-title":"Neutrophils and immunity: challenges and opportunities","volume":"6","author":"Nathan","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02127","article-title":"Enhanced neutrophil immune homeostasis due to deletion of PHLPP","volume":"2127","author":"Ran","year":"2019","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1083\/jcb.200202114","article-title":"An intracellular signaling hierarchy determines direction of migration in opposing chemotactic gradients","volume":"159","author":"Heit","year":"2002","journal-title":"J Cell Biol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.2MA1214-599R","article-title":"MEK-independent ERK activation in human neutrophils and its impact on functional responses","volume":"98","author":"Simard","year":"2015","journal-title":"J Leukocyte Biol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2242","article-title":"Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R","volume":"16","author":"Wilhelm","year":"2010","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130084","article-title":"The Nlrp3 inflammasome regulates acute graft-versus-host disease","volume":"210","author":"Jankovic","year":"2013","journal-title":"J Exp Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2015.03.028","article-title":"N-formyl peptides drive mitochondrial damage associated molecular pattern induced neutrophil activation through ERK1\/2 and P38 MAP kinase signalling pathways","volume":"46","author":"Hazeldine","year":"2015","journal-title":"Injury"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636954","article-title":"Neutrophil extracellular traps activate proinflammatory functions of human neutrophils","volume":"12","author":"D\u00f6mer","year":"2021","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M007527200","article-title":"Tumor necrosis factor-\u03b1 activation of the c-jun n-terminal kinase pathway in human neutrophils: integrin involvement in a pathway leading from cytoplasmic tyrosine kinases to apoptosis","volume":"276","author":"Avdi","year":"2001","journal-title":"J Biol Chem"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2014.12.006","article-title":"PI3K signalling in inflammation","volume":"1851","author":"Hawkins","year":"2015","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and structural analysis of common cancer-associated KRAS mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1263-y","article-title":"RAF Kinase dimerization: Implications for drug discovery and clinical outcomes","volume":"39","author":"Brummer","year":"2020","journal-title":"Oncogene"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.254","article-title":"Essential, non-redundant roles of b-raf and raf-1 in ras-driven skin tumorigenesis","volume":"32","author":"Kern","year":"2013","journal-title":"Oncogene"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.008","article-title":"Raf-1 addiction in ras-induced skin carcinogenesis","volume":"16","author":"Ehrenreiter","year":"2009","journal-title":"Cancer Cell"},{"key":"B105","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ccell.2019.03.002","article-title":"Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and c-RAF","volume":"35","author":"Blasco","year":"2019","journal-title":"Cancer Cell"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1515","article-title":"Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition","volume":"72","author":"Hoeflich","year":"2012","journal-title":"Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6672","article-title":"A small molecule disruptor of Rb\/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice","volume":"68","author":"Kinkade","year":"2008","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.080583397","article-title":"Raf induces NF-\u03baB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation","volume":"97","author":"Baumann","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81383-5","article-title":"Bcl-2 targets the protein kinase raf-1 to mitochondria","volume":"87","author":"Wang","year":"1996","journal-title":"Cell"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200504137","article-title":"Raf-1 sets the threshold of fas sensitivity by modulating rok-\u03b1 signaling","volume":"171","author":"Piazzolla","year":"2005","journal-title":"J Cell Biol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aai8482","article-title":"RAF1\/BRAF dimerization integrates the signal from RAS to ERK and ROK\u03b1","volume":"10","author":"Varga","year":"2017","journal-title":"Sci Signaling"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1452","article-title":"Allele-specific mechanisms of activation of MEK1 mutants determine their properties","volume":"8","author":"Gao","year":"2018","journal-title":"Cancer Discov"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0022-x","article-title":"Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition","volume":"24","author":"Wong","year":"2018","journal-title":"Nat Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1694-1","article-title":"(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"B116","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume-title":"Clin Cancer Res","author":"Nakajima","year":"2022"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nature12796","article-title":"K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p. G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non\u2013Small-Cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med (online ahead of print)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/ijms20061483","article-title":"Targeting the ERK signaling pathway in melanoma","volume":"20","author":"Savoia","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1042\/BST20200485","article-title":"Inhibition of RAF dimers: it takes two to tango","volume":"49","author":"Cook","year":"2021","journal-title":"Biochem Soc Trans"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76539","article-title":"BRAF inhibitor\u2013associated ERK activation drives development of chronic lymphocytic leukemia","volume":"124","author":"Yaktapour","year":"2014","journal-title":"J Clin Invest"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-680074","article-title":"BRAF inhibition in hairy cell leukemia with low-dose vemurafenib","volume":"127","author":"Dietrich","year":"2016","journal-title":"Blood J Am Soc Hematol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/nature08902","article-title":"RAF Inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0274-5","article-title":"RAF Inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling","volume":"25","author":"Yao","year":"2019","journal-title":"Nat Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-10-0044","article-title":"C-raf is required for the initiation of lung cancer by K-RasG12D","volume":"1","author":"Karreth","year":"2011","journal-title":"Cancer Discov"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.01.023","article-title":"Selective requirement of PI3K\/PDK1 signaling for kras oncogene-driven pancreatic cell plasticity and cancer","volume":"23","author":"Eser","year":"2013","journal-title":"Cancer Cell"},{"key":"B131","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ccell.2017.12.014","article-title":"C-RAF ablation induces regression of advanced Kras\/Trp53 mutant lung adenocarcinomas by a mechanism independent of MAPK signaling","volume":"33","author":"Sanclemente","year":"2018","journal-title":"Cancer Cell"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic strategies to target RAS-mutant cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.01.017","article-title":"C-raf in KRas mutant cancers: A moving target","volume":"33","author":"McCormick","year":"2018","journal-title":"Cancer Cell"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1700247","DOI":"10.1002\/bies.201700247","article-title":"PROTACs: an emerging targeting technique for protein degradation in drug discovery","volume":"40","author":"Gu","year":"2018","journal-title":"BioEssays"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.01.008","article-title":"RAF1 kinase activity is dispensable for KRAS\/p53 mutant lung tumor progression","volume":"39","author":"Sanclemente","year":"2021","journal-title":"Cancer Cell"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.06.079947","article-title":"Identification of PDE6D as a potential target of sorafenib via PROTAC technology","author":"Li","year":"2020","journal-title":"bioRxiv"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting alterations in the RAF\u2013MEK pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with kras-mutant advanced non\u2013small cell lung cancer: The select-1 randomized clinical trial","volume":"317","author":"J\u00e4nne","year":"2017","journal-title":"Jama"},{"key":"B139","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1200\/jco.2013.31.4_suppl.291","article-title":"A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas","volume":"31","author":"Infante","year":"2013","journal-title":"Am Soc Clin Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0396","article-title":"Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer","volume":"76","author":"Oddo","year":"2016","journal-title":"Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS\u2013ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B142","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.celrep.2014.02.045","article-title":"Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3","volume":"7","author":"Sun","year":"2014","journal-title":"Cell Rep"},{"key":"B143","doi-asserted-by":"publisher","first-page":"xi41","DOI":"10.1016\/S0923-7534(20)32033-0","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition","volume":"23","author":"Ebi","year":"2012","journal-title":"Ann Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0462","article-title":"Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution","volume":"4","author":"Misale","year":"2014","journal-title":"Cancer Discov"},{"key":"B145","doi-asserted-by":"publisher","first-page":"102137","DOI":"10.1016\/j.ctrv.2020.102137","article-title":"MEK inhibitor resistance mechanisms and recent developments in combination trials","volume":"92","author":"Kun","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"New Engl J Med"},{"key":"B147","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s43018-021-00221-9","article-title":"Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma","volume":"2","author":"Haas","year":"2021","journal-title":"Nat Cancer"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(03)00091-4","article-title":"The \u2018Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling","volume":"28","author":"Neel","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-008-9126-y","article-title":"The tyrosine phosphatase Shp2 (PTPN11) in cancer","volume":"27","author":"Chan","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"B150","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.2741\/3051","article-title":"Protein tyrosine phosphatases in the JAK\/STAT pathway","volume":"13","author":"Xu","year":"2008","journal-title":"Front Biosci: J Virtual Library"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0024-8","article-title":"Mutant KRAS-driven cancers depend on PTPN11\/SHP2 phosphatase","volume":"24","author":"Ruess","year":"2018","journal-title":"Nat Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0444","article-title":"SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models","volume":"8","author":"Fedele","year":"2018","journal-title":"Cancer Discov"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1812963116","article-title":"Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS\u2013SOS1 interaction","volume":"116","author":"Hillig","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0666","article-title":"Small molecule\u2013mediated acti34 8vation of RAS elicits biphasic modulation of phospho-ERK levels that are regulated through negative feedback on SOS1","volume":"17","author":"Howes","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2021.02.014","article-title":"Targeting son of sevenless 1: the pacemaker of KRAS","volume":"62","author":"Kessler","year":"2021","journal-title":"Curr Opin Chem Biol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"B158","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1158\/0008-5472.CAN-17-2084","article-title":"KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment","volume":"78","author":"Carvalho","year":"2018","journal-title":"Cancer Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2019.03.002","article-title":"Targeting the untargetable KRAS in cancer therapy","volume":"9","author":"Liu","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.08.019","article-title":"Immunomodulatory effects of BRAF and MEK inhibitors: Implications for melanoma therapy","volume":"136","author":"Kuske","year":"2018","journal-title":"Pharmacol Res"},{"key":"B162","doi-asserted-by":"publisher","first-page":"e1052212","DOI":"10.1080\/2162402X.2015.1052212","article-title":"Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma","volume":"5","author":"Homet Moreno","year":"2016","journal-title":"Oncoimmunology"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1549407","article-title":"Oncogenic ras-induced secretion of IL6 is required for tumorigenesis","volume":"21","author":"Ancrile","year":"2007","journal-title":"Genes Dev"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2388","article-title":"IL6 trans-signaling promotes KRAS-driven lung carcinogenesis","volume":"76","author":"Brooks","year":"2016","journal-title":"Cancer Res"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.03.009","article-title":"Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer","volume":"19","author":"Lesina","year":"2011","journal-title":"Cancer Cell"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0908","article-title":"STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis","volume":"71","author":"Corcoran","year":"2011","journal-title":"Cancer Res"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1558-T","article-title":"Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance","volume":"73","author":"Zhang","year":"2013","journal-title":"Cancer Res"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.09.028","article-title":"Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis","volume":"6","author":"Sparmann","year":"2004","journal-title":"Cancer Cell"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201902990R","article-title":"CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma","volume":"34","author":"Awaji","year":"2020","journal-title":"FASEB J"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.12.006","article-title":"KrasG12D-induced IKK2\/\u03b2\/NF-\u03baB activation by IL-1\u03b1 and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma","volume":"21","author":"Ling","year":"2012","journal-title":"Cancer Cell"},{"key":"B172","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/2159-8290.CD-14-0474","article-title":"Mutant KRAS\u2013induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions","volume":"5","author":"Liou","year":"2015","journal-title":"Cancer Discov"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1319051111","article-title":"T Helper 17 cells play a critical pathogenic role in lung cancer","volume":"111","author":"Chang","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.03.014","article-title":"Oncogenic kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia","volume":"25","author":"McAllister","year":"2014","journal-title":"Cancer Cell"},{"key":"B175","doi-asserted-by":"publisher","first-page":"247","DOI":"10.18632\/oncoscience.151","article-title":"Inflammatory macrophages in pancreatic acinar cell metaplasia and initiation of pancreatic cancer","volume":"2","author":"Liou","year":"2015","journal-title":"Oncoscience"},{"key":"B176","doi-asserted-by":"publisher","first-page":"e1008794","DOI":"10.1080\/2162402X.2015.1008794","article-title":"The crosstalk between acinar cells with kras mutations and M1-polarized macrophages leads to initiation of pancreatic precancerous lesions","volume":"4","author":"Storz","year":"2015","journal-title":"Oncoimmunology"},{"key":"B177","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cell.2016.07.046","article-title":"\u03b3\u03b4 T cells support pancreatic oncogenesis by restraining \u03b1\u03b2 T cell activation","volume":"166","author":"Daley","year":"2016","journal-title":"Cell"},{"key":"B178","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-15497-1","article-title":"Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166626","article-title":"RAS\u2013mitogen-activated protein kinase signal is required for enhanced PD-L1 expression in human lung cancers","volume":"11","author":"Sumimoto","year":"2016","journal-title":"PloS One"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2005-z","article-title":"KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma","volume":"66","author":"Chen","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT\u2013mTOR pathway in non\u2013small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.95","article-title":"PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes","volume":"29","author":"Rosenbaum","year":"2016","journal-title":"Modern Pathol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e14500","article-title":"Expression of PD-L1 in colorectal cancer that lack mutations in RAS or TP53 genes","volume":"35","author":"Albitar","year":"2017","journal-title":"Am Soc Clin Oncol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0241","article-title":"Mutant KRAS conversion of conventional T cells into regulatory T cells","volume":"4","author":"Zdanov","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0030","article-title":"BRAFV600E co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma","volume":"3","author":"Bradley","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"B190","doi-asserted-by":"publisher","first-page":"e73616","DOI":"10.1371\/journal.pone.0073616","article-title":"Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-\u03b3","volume":"8","author":"Petanidis","year":"2013","journal-title":"PloS One"},{"key":"B191","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"key":"B192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-15979-2","article-title":"Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy","volume":"11","author":"Baumann","year":"2020","journal-title":"Nat Commun"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(00)00083-2","article-title":"Signal transduction by the TCR for antigen","volume":"12","author":"Kane","year":"2000","journal-title":"Curr Opin Immunol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0160","article-title":"Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor","volume":"2","author":"Callahan","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","journal-title":"Sci Trans Med"},{"key":"B196","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","article-title":"MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects","volume":"22","author":"Verma","year":"2021","journal-title":"Nat Immunol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","article-title":"Memory T cell, exhaustion, and tumor immunity","volume":"43","author":"Ando","year":"2020","journal-title":"J Immunol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"108328","DOI":"10.1016\/j.celrep.2020.108328","article-title":"Nr4a1 and Nr4a3 reporter mice are differentially sensitive to T cell receptor signal strength and duration","volume":"33","author":"Jennings","year":"2020","journal-title":"Cell Reports"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224600","article-title":"MEK inhibition suppresses b regulatory cells and augments anti-tumor immunity","volume":"14","author":"Yarchoan","year":"2019","journal-title":"PloS One"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.6.3855","article-title":"Inhibition of the MEK\/ERK signaling pathway blocks a subset of b cell responses to antigen","volume":"166","author":"Richards","year":"2001","journal-title":"J Immunol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"60858","DOI":"10.18632\/oncotarget.11504","article-title":"Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function","volume":"7","author":"Manzini","year":"2016","journal-title":"Oncotarget"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03231-1","article-title":"Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population","volume":"356","author":"Imai","year":"2000","journal-title":"Lancet"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P","article-title":"The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma","volume":"79","author":"Coca","year":"1997","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V","article-title":"Prognostic value of intratumoral natural killer cells in gastric carcinoma","volume":"88","author":"Ishigami","year":"2000","journal-title":"Cancer"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(01)00292-6","article-title":"Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer","volume":"35","author":"Villegas","year":"2002","journal-title":"Lung Cancer"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M408356200","article-title":"Interleukins 2 and 15 regulate Ets1 expression via ERK1\/2 and MNK1 in human natural killer cells","volume":"280","author":"Grund","year":"2005","journal-title":"J Biol Chem"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2017.08.009","article-title":"The synergistic effects of combining TLR ligand based adjuvants on the cytokine response are dependent upon p38\/JNK signalling","volume":"99","author":"Fischetti","year":"2017","journal-title":"Cytokine"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134290","article-title":"MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC","volume":"5","author":"Franklin","year":"2020","journal-title":"JCI Insight"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-071761","article-title":"Activation of mitogen-activated protein kinase kinase (MEK)\/extracellular signal\u2013regulated kinase (ERK) signaling pathway is involved in myeloid lineage commitment","volume":"110","author":"Hsu","year":"2007","journal-title":"Blood J Am Soc Hematol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66167","article-title":"Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require erk","volume":"123","author":"Staser","year":"2012","journal-title":"J Clin Invest"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1308","article-title":"Trametinib drives t-cell\u2013dependent control of KRAS-mutated tumors by inhibiting pathological myelopoiesis","volume":"76","author":"Allegrezza","year":"2016","journal-title":"Cancer Res"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.647312","article-title":"Targeting the MDSCs of tumors In situ with inhibitors of the MAPK signaling pathway to promote tumor regression","volume":"11","author":"Yu","year":"2021","journal-title":"Front Oncol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0275","article-title":"Oncogenic KrasG12D activation in the nonhematopoietic bone marrow microenvironment causes myelodysplastic syndrome in mice","volume":"19","author":"Osswald","year":"2021","journal-title":"Mol Cancer Res"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0177","article-title":"Kinase regulation of human MHC class I molecule expression on cancer cells","volume":"4","author":"Brea","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B215","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.celrep.2019.03.066","article-title":"Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in murine kras mutant lung cancer","volume":"27","author":"Choi","year":"2019","journal-title":"Cell Rep"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.01.128","article-title":"Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma","volume":"484","author":"Liu","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B218","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-017-0268-8","article-title":"The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment","volume":"5","author":"Poon","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0023-9","article-title":"SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo","volume":"24","author":"Mainardi","year":"2018","journal-title":"Nat Med"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0368-8","article-title":"Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer","volume":"25","author":"Bryant","year":"2019","journal-title":"Nat Med"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0367-9","article-title":"Protective autophagy elicited by RAF\u2192 MEK\u2192 ERK inhibition suggests a treatment strategy for RAS-driven cancers","volume":"25","author":"Kinsey","year":"2019","journal-title":"Nat Med"},{"key":"B222","doi-asserted-by":"publisher","first-page":"TPS450","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS450","article-title":"MEKiAUTO: A phase I\/II open-label study of combination therapy with the MEK inhibitor cobimetinib, immune-checkpoint blockade with atezolizumab, and the AUTOphagy inhibitor hydroxychloroquine in KRAS-mutated advanced malignancies","volume":"39","author":"Raufi","year":"2021","journal-title":"Am Soc Clin Oncol"},{"key":"B223","doi-asserted-by":"publisher","first-page":"107764","DOI":"10.1016\/j.celrep.2020.107764","article-title":"Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers","volume":"31","author":"Ozkan-Dagliyan","year":"2020","journal-title":"Cell Rep"},{"key":"B224","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-16952-9","article-title":"Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours","volume":"11","author":"Fernandes Neto","year":"2020","journal-title":"Nat Commun"},{"key":"B225","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.ccell.2021.07.023","article-title":"Anti-PD-1\/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"New Engl J Med"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"New Engl J Med"},{"key":"B228","doi-asserted-by":"publisher","first-page":"e1238557","DOI":"10.1080\/2162402X.2016.1238557","article-title":"Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma","volume":"5","author":"Deken","year":"2016","journal-title":"Oncoimmunology"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.12.009","article-title":"MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells","volume":"40","author":"Limagne","year":"2022","journal-title":"Cancer Cell"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4369","article-title":"An approach to suppress the evolution of resistance in BRAF V600E-mutant cancer","volume":"23","author":"Xue","year":"2017","journal-title":"Nat Med"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00776-6","article-title":"Phase ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors","volume":"38","author":"Shapiro","year":"2020","journal-title":"Investigational New Drugs"},{"key":"B232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-26572-6","article-title":"Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial","volume":"12","author":"Gonzalez-Cao","year":"2021","journal-title":"Nat Commun"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04066-4","article-title":"Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer","volume":"85","author":"Huijberts","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2615-5","article-title":"Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma","volume":"75","author":"Tolcher","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"B235","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/onco.13631","article-title":"Phase I study of afatinib and selumetinib in patients with KRAS-mutated colorectal, non-small cell lung, and pancreatic cancer","volume":"26","author":"Brummelen","year":"2021","journal-title":"Oncol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1060-8","article-title":"Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial","volume":"26","author":"Algazi","year":"2020","journal-title":"Nat Med"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30464-2","article-title":"Intermittent schedules of the oral RAF\u2013MEK inhibitor CH5126766\/VS-6766 in patients with RAS\/RAF-mutant solid tumours and multiple myeloma: A single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study","volume":"21","author":"Guo","year":"2020","journal-title":"Lancet Oncol"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0742","article-title":"First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK\/RAF inhibitor in patients with solid tumors","volume":"18","author":"Martinez-Garcia","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.931774\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T17:27:59Z","timestamp":1676222879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.931774\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":238,"alternative-id":["10.3389\/fonc.2022.931774"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.931774","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"article-number":"931774"}}